Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer’s disease and supporting differential diagnosis
Alzheimer’s disease (AD) is on the rise all over the world, and brings with it great challenges to medical care and heavy burdens to family and society. Accurate diagnosis and differential diagnosis are of great importance. Tau positron emission tomography (PET) might offer novel insights and be of...
Gespeichert in:
| Veröffentlicht in: | Annals of nuclear medicine 2021-02, Vol.35 (2), p.139-147 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 147 |
|---|---|
| container_issue | 2 |
| container_start_page | 139 |
| container_title | Annals of nuclear medicine |
| container_volume | 35 |
| creator | Zhang, Wenyan Xu, Shuoyan Yu, Hongmei Li, Xuena Jin, Zhuangzhuang Li, Yaming He, Zhiyi |
| description | Alzheimer’s disease (AD) is on the rise all over the world, and brings with it great challenges to medical care and heavy burdens to family and society. Accurate diagnosis and differential diagnosis are of great importance. Tau positron emission tomography (PET) might offer novel insights and be of great assistance in monitoring disease progression and supporting the differential diagnosis.
18
F-AV-1451, as the first Tau PET imaging agent approved by the Food and Drug Administration (FDA), has been of great potential in clinical trials. Here, we reviewed the synthesis and characteristics of
18
F-AV-1451 and its role in monitoring AD progression and supporting the differential diagnosis. |
| doi_str_mv | 10.1007/s12149-020-01566-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2478773993</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2478773993</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2214-1fbcf31df43f035ae0be45f090072ea20a1cb369ce01f25b9c9efa38d39f4b363</originalsourceid><addsrcrecordid>eNp9kc9qFTEUxoNU8Lb6Aq4CbrqJ5t_8yfJSWhUKLVLdhtyZk2nK3GTMmRHqytdw75P1Scz0FgouXIWQ3_flO-cj5K3g7wXnzQcUUmjDuOSMi6qumX5BNqKtNau1Ukdkw43QrBFt84ocI95xLtuqlRvy54vrQ3LdHH4Axfs43wIGpMnT2S30-vyGhr0bQhyoGyDOVLQXbPuNCV0J6mJPw4w0pxFoiHSfYphTXuFiQ6echgyIIcXVbzv-vIWwh_zw6zfSPiA4hEcPXKYp5XnV9cF7yOWj4MZycUNMJc5r8tK7EeHN03lCvl6c35x9YpdXHz-fbS9ZJ8v4TPhd55XovVaeq8oB34GuPDdlQxKc5E50O1WbDrjwstqZzoB3qu2V8bo8qBNyevAt0b8vgLPdB-xgHF2EtKCVummbRhmjCvruH_QuLTmWdIUyouZNI1dKHqguJ8QM3k657DPfW8HtWpw9FGdLcfaxOKuLSB1EOK27hPxs_R_VX_c3nhE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2491607723</pqid></control><display><type>article</type><title>Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer’s disease and supporting differential diagnosis</title><source>SpringerLink Journals - AutoHoldings</source><creator>Zhang, Wenyan ; Xu, Shuoyan ; Yu, Hongmei ; Li, Xuena ; Jin, Zhuangzhuang ; Li, Yaming ; He, Zhiyi</creator><creatorcontrib>Zhang, Wenyan ; Xu, Shuoyan ; Yu, Hongmei ; Li, Xuena ; Jin, Zhuangzhuang ; Li, Yaming ; He, Zhiyi</creatorcontrib><description>Alzheimer’s disease (AD) is on the rise all over the world, and brings with it great challenges to medical care and heavy burdens to family and society. Accurate diagnosis and differential diagnosis are of great importance. Tau positron emission tomography (PET) might offer novel insights and be of great assistance in monitoring disease progression and supporting the differential diagnosis.
18
F-AV-1451, as the first Tau PET imaging agent approved by the Food and Drug Administration (FDA), has been of great potential in clinical trials. Here, we reviewed the synthesis and characteristics of
18
F-AV-1451 and its role in monitoring AD progression and supporting the differential diagnosis.</description><identifier>ISSN: 0914-7187</identifier><identifier>EISSN: 1864-6433</identifier><identifier>DOI: 10.1007/s12149-020-01566-4</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Alzheimer's disease ; Clinical trials ; Diagnosis ; Differential diagnosis ; Fluorine isotopes ; Imaging ; Medical diagnosis ; Medical imaging ; Medicine ; Medicine & Public Health ; Monitoring ; Neurodegenerative diseases ; Nuclear Medicine ; Positron emission ; Positron emission tomography ; Radiology ; Review Article ; Synthesis ; Tau protein ; Telemedicine ; Tomography</subject><ispartof>Annals of nuclear medicine, 2021-02, Vol.35 (2), p.139-147</ispartof><rights>The Japanese Society of Nuclear Medicine 2021</rights><rights>The Japanese Society of Nuclear Medicine 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2214-1fbcf31df43f035ae0be45f090072ea20a1cb369ce01f25b9c9efa38d39f4b363</citedby><cites>FETCH-LOGICAL-c2214-1fbcf31df43f035ae0be45f090072ea20a1cb369ce01f25b9c9efa38d39f4b363</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12149-020-01566-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12149-020-01566-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Zhang, Wenyan</creatorcontrib><creatorcontrib>Xu, Shuoyan</creatorcontrib><creatorcontrib>Yu, Hongmei</creatorcontrib><creatorcontrib>Li, Xuena</creatorcontrib><creatorcontrib>Jin, Zhuangzhuang</creatorcontrib><creatorcontrib>Li, Yaming</creatorcontrib><creatorcontrib>He, Zhiyi</creatorcontrib><title>Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer’s disease and supporting differential diagnosis</title><title>Annals of nuclear medicine</title><addtitle>Ann Nucl Med</addtitle><description>Alzheimer’s disease (AD) is on the rise all over the world, and brings with it great challenges to medical care and heavy burdens to family and society. Accurate diagnosis and differential diagnosis are of great importance. Tau positron emission tomography (PET) might offer novel insights and be of great assistance in monitoring disease progression and supporting the differential diagnosis.
18
F-AV-1451, as the first Tau PET imaging agent approved by the Food and Drug Administration (FDA), has been of great potential in clinical trials. Here, we reviewed the synthesis and characteristics of
18
F-AV-1451 and its role in monitoring AD progression and supporting the differential diagnosis.</description><subject>Alzheimer's disease</subject><subject>Clinical trials</subject><subject>Diagnosis</subject><subject>Differential diagnosis</subject><subject>Fluorine isotopes</subject><subject>Imaging</subject><subject>Medical diagnosis</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monitoring</subject><subject>Neurodegenerative diseases</subject><subject>Nuclear Medicine</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Radiology</subject><subject>Review Article</subject><subject>Synthesis</subject><subject>Tau protein</subject><subject>Telemedicine</subject><subject>Tomography</subject><issn>0914-7187</issn><issn>1864-6433</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kc9qFTEUxoNU8Lb6Aq4CbrqJ5t_8yfJSWhUKLVLdhtyZk2nK3GTMmRHqytdw75P1Scz0FgouXIWQ3_flO-cj5K3g7wXnzQcUUmjDuOSMi6qumX5BNqKtNau1Ukdkw43QrBFt84ocI95xLtuqlRvy54vrQ3LdHH4Axfs43wIGpMnT2S30-vyGhr0bQhyoGyDOVLQXbPuNCV0J6mJPw4w0pxFoiHSfYphTXuFiQ6echgyIIcXVbzv-vIWwh_zw6zfSPiA4hEcPXKYp5XnV9cF7yOWj4MZycUNMJc5r8tK7EeHN03lCvl6c35x9YpdXHz-fbS9ZJ8v4TPhd55XovVaeq8oB34GuPDdlQxKc5E50O1WbDrjwstqZzoB3qu2V8bo8qBNyevAt0b8vgLPdB-xgHF2EtKCVummbRhmjCvruH_QuLTmWdIUyouZNI1dKHqguJ8QM3k657DPfW8HtWpw9FGdLcfaxOKuLSB1EOK27hPxs_R_VX_c3nhE</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Zhang, Wenyan</creator><creator>Xu, Shuoyan</creator><creator>Yu, Hongmei</creator><creator>Li, Xuena</creator><creator>Jin, Zhuangzhuang</creator><creator>Li, Yaming</creator><creator>He, Zhiyi</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20210201</creationdate><title>Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer’s disease and supporting differential diagnosis</title><author>Zhang, Wenyan ; Xu, Shuoyan ; Yu, Hongmei ; Li, Xuena ; Jin, Zhuangzhuang ; Li, Yaming ; He, Zhiyi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2214-1fbcf31df43f035ae0be45f090072ea20a1cb369ce01f25b9c9efa38d39f4b363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alzheimer's disease</topic><topic>Clinical trials</topic><topic>Diagnosis</topic><topic>Differential diagnosis</topic><topic>Fluorine isotopes</topic><topic>Imaging</topic><topic>Medical diagnosis</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monitoring</topic><topic>Neurodegenerative diseases</topic><topic>Nuclear Medicine</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Radiology</topic><topic>Review Article</topic><topic>Synthesis</topic><topic>Tau protein</topic><topic>Telemedicine</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Wenyan</creatorcontrib><creatorcontrib>Xu, Shuoyan</creatorcontrib><creatorcontrib>Yu, Hongmei</creatorcontrib><creatorcontrib>Li, Xuena</creatorcontrib><creatorcontrib>Jin, Zhuangzhuang</creatorcontrib><creatorcontrib>Li, Yaming</creatorcontrib><creatorcontrib>He, Zhiyi</creatorcontrib><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Wenyan</au><au>Xu, Shuoyan</au><au>Yu, Hongmei</au><au>Li, Xuena</au><au>Jin, Zhuangzhuang</au><au>Li, Yaming</au><au>He, Zhiyi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer’s disease and supporting differential diagnosis</atitle><jtitle>Annals of nuclear medicine</jtitle><stitle>Ann Nucl Med</stitle><date>2021-02-01</date><risdate>2021</risdate><volume>35</volume><issue>2</issue><spage>139</spage><epage>147</epage><pages>139-147</pages><issn>0914-7187</issn><eissn>1864-6433</eissn><abstract>Alzheimer’s disease (AD) is on the rise all over the world, and brings with it great challenges to medical care and heavy burdens to family and society. Accurate diagnosis and differential diagnosis are of great importance. Tau positron emission tomography (PET) might offer novel insights and be of great assistance in monitoring disease progression and supporting the differential diagnosis.
18
F-AV-1451, as the first Tau PET imaging agent approved by the Food and Drug Administration (FDA), has been of great potential in clinical trials. Here, we reviewed the synthesis and characteristics of
18
F-AV-1451 and its role in monitoring AD progression and supporting the differential diagnosis.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><doi>10.1007/s12149-020-01566-4</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0914-7187 |
| ispartof | Annals of nuclear medicine, 2021-02, Vol.35 (2), p.139-147 |
| issn | 0914-7187 1864-6433 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2478773993 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Alzheimer's disease Clinical trials Diagnosis Differential diagnosis Fluorine isotopes Imaging Medical diagnosis Medical imaging Medicine Medicine & Public Health Monitoring Neurodegenerative diseases Nuclear Medicine Positron emission Positron emission tomography Radiology Review Article Synthesis Tau protein Telemedicine Tomography |
| title | Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer’s disease and supporting differential diagnosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T19%3A24%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radioactive%20synthesis%20of%20tau%20PET%20imaging%20agent%2018F-AV-1451%20and%20its%20role%20in%20monitoring%20the%20progression%20of%20Alzheimer%E2%80%99s%20disease%20and%20supporting%20differential%20diagnosis&rft.jtitle=Annals%20of%20nuclear%20medicine&rft.au=Zhang,%20Wenyan&rft.date=2021-02-01&rft.volume=35&rft.issue=2&rft.spage=139&rft.epage=147&rft.pages=139-147&rft.issn=0914-7187&rft.eissn=1864-6433&rft_id=info:doi/10.1007/s12149-020-01566-4&rft_dat=%3Cproquest_cross%3E2478773993%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2491607723&rft_id=info:pmid/&rfr_iscdi=true |